Silvia Formenti, MD
Radiation Oncology · New York, NYNPI 1568463339
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $46,000 of the $57,351 with a category attached, or 80.2%. 13 manufacturers reported payments, led by Astrazeneca UK Limited at 44.3% of the total. Reporting peaked in 2022 at $15,462 and has fallen 99.8% since, to $26 in 2025. Among radiation oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 53 payments — averaging $1082.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$25K
- F. Hoffmann-la Roche AG$8K
- Accuray Incorporated$7K
- Merck$6K
- EMD Serono, Inc.$4K
- AstraZeneca$3K
- plus $5K from 7 others
Across 33 payments — averaging $79,664 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.4M
- Regeneron$99K
- Varian Medical Systems, Inc.$86K
- AstraZeneca$24K
- Siemens Medical Solutions USA, Inc.$17K
What the payments were for
- Consulting fees$46,00080%
- Speaking & faculty fees$7,00912%
- Travel & lodging$2,8305%
- Food & beverage$1,5133%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 19 | $25,381 |
| F. Hoffmann-la Roche AG | 5 | $7,600 |
| Accuray Incorporated | 8 | $6,613 |
| Merck | 8 | $6,456 |
| EMD Serono, Inc. | 1 | $3,750 |
| AstraZeneca | 1 | $3,000 |
| Genentech, Inc. | 1 | $2,310 |
| Boehringer Ingelheim International GmbH | 3 | $1,500 |
| Siemens Medical Solutions USA, Inc. | 3 | $371 |
| Bayer | 1 | $205 |
| Astrazeneca AB | 1 | $92 |
| Elekta, Inc. | 1 | $47 |
| Boehringer Ingelheim | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CyberKnife System$5,413
- TomoTherapy System$5,413
- IMFINZI$2,643
- Varian Ethos Treatment Planning$261
- TrueBeam$109
How this compares
$57,351 in reported general payments places this provider in the 95th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in New York
- Michael ZelefskyNew York$946K
- Nancy LeeNew York$233K
- Robert SamsteinNew York$125K
- Jalal AhmedNew York$100K
- Charles SimoneNew York$84K
- Brandon ImberNew York$44K
- Himanshu NagarNew York$43K
- Chiaojung TsaiNew York$38K
- Christopher BarkerNew York$32K
- Yoshiya YamadaNew York$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.